AIM ImmunoTech prices $2.65 million registered direct offering and private placement

AIM ImmunoTech Inc.

Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M.
Also issued pre-funded warrants for 1,782,616 shares at $0.001 exercise price and Class J warrants for 10,216,476 shares at $0.5189.
Offering includes placement agent warrants for 306,494 shares at $0.6486 per share; Ladenburg Thalmann acted as placement agent.
Net proceeds will fund clinical trial activities, manufacture of clinical drug supply, and working capital.
Closing expected on or about June 10, 2026, subject to customary conditions.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

AIM ImmunoTech Inc. issued up to 1,782,616 shares of Common Stock of warrant to institutional investors.

Security: warrant
Shares: up to 1,782,616 shares of Common Stock
Purchaser: institutional investors

Exact text from the filing

pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,782,616 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

AIM ImmunoTech Inc. issued 771,503 shares of common stock to institutional investors for $0.5189 per share.

Security: common stock
Shares: 771,503 shares
Purchaser: institutional investors
Consideration: $0.5189 per share

Exact text from the filing

the Company also agreed to issue and sell to such Investors, in a concurrent private placement, 771,503 shares of Common Stock at a per share price of $0.5189 (the “Unregistered Shares”)

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

AIM ImmunoTech Inc. issued 306,494 shares of Common Stock of warrant to Ladenburg Thalmann & Co. Inc..

Security: warrant
Shares: 306,494 shares of Common Stock
Purchaser: Ladenburg Thalmann & Co. Inc.

Exact text from the filing

The Company also agreed to issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 306,494 shares of Common Stock (the “Placement Agent Warrant Shares”)

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

AIM ImmunoTech Inc. issued up to 10,216,476 shares of Common Stock of warrant to institutional investors.

Security: warrant
Shares: up to 10,216,476 shares of Common Stock
Purchaser: institutional investors

Exact text from the filing

Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock (the “Class J Warrant Shares”), at an exercise price of $0.5189 per share

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Securities Purchase Agreement with institutional investors valued at Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro (effective 2026-06-09).

Action: entry
Agreement: equity purchase
Counterparty: institutional investors
Value: Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro
Effective: 2026-06-09

Exact text from the filing

On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189 per share (such registered direct offering, the “Registered Offering”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. valued at Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p (effective 2026-06-09).

Action: entry
Agreement: underwriting
Counterparty: Ladenburg Thalmann & Co. Inc.
Value: Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p
Effective: 2026-06-09

Exact text from the filing

In connection with the Offerings, the Company also entered into a placement agency agreement, dated June 9, 2026 (the “Placement Agency Agreement”), with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 8.0%, and a management fee equal to 0.75%, of the aggregate gross proceeds of the Offerings, and reimbursed the Placement Agent for certain expenses and legal fees.

View on SEC.gov

226 equity issuances filed in the last 30 days. Browse all equity issuances →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-028283

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.